Low-cost mass screening for breast cancer with mammography.

: Breast cancer is the most common type of malignancy among ladies (around 30% of newly diagnosed patients every year). To date, various modern treatment modalities for breast cancer, such as radiotherapy, surgical method, hormonal therapy, and chemotherapeutic drug utilisation, are available. However, adverse drug reactions, therapeutic resistance, metastasis, or cancer reoccurrence chances remain the primary causes of mortality for breast cancer patients. To overcome all the potential drawbacks, we need to investigate novel techniques and strategies previously not considered and treat breast cancer effectively with safety and efficacy. For centuries, we utilise phytochemicals to treat various diseases because of their safety, low-cost & least or no side effects. Recently, naturally produced phytochemicals gain immense attention as potential breast cancer therapeutics because of their ideal characteristics; for instance, they operate via modulating molecular pathways associated with cancer growth and progression. The primary mechanism involves inhibition of cell proliferation, angiogenesis, migration, invasion, increasing anti-oxidant status, initiation of the arrest of the cell cycle, and apoptosis. Remedial viability gets effectively enhanced when phytochemicals work as adjuvants with chemotherapeutic drugs. This comprehensive review revolves around the latest chemopreventive, chemotherapeutic, and chemoprotective treatments with their molecular mechanisms to treat breast cancer by utilising phytochemicals such as vinca alkaloids, resveratrol, curcumin, paclitaxel, silibinin, quercetin, genistein and epigallocatechin gallate. The authors wish to extend the field of phytochemical study for its scientific validity and its druggability.

Download Full-text

Prospective Randomized Trial of Use of In-House Prepared Low-Cost Radiopharmaceutical Versus Commercial Radiopharmaceutical for Sentinel Lymph Node Biopsy in Patients with Early Stage Invasive Breast Cancer

World Journal of Surgery ◽

10.1007/s00268-018-4504-2 ◽

2018 ◽

Vol 42 (5) ◽

pp. 1391-1395

Author(s):

Gaurav Agarwal ◽

Sendhil Rajan ◽

Sabaretnam Mayilvaganan ◽

Anjali Mishra ◽

Narendra Krishnani ◽

...

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Sentinel Lymph Node ◽

Sentinel Lymph Node Biopsy ◽

Randomized Trial ◽

Invasive Breast Cancer ◽

Early Stage ◽

Low Cost ◽

Lymph Node Biopsy ◽

Node Biopsy

Download Full-text

Early detection of breast cancer. Role of sonography for mass-screening. International stand of technique and organisation

Journal of Cancer Research and Clinical Oncology ◽

10.1007/bf02579781 ◽

1986 ◽

Vol 111 (S1) ◽

pp. S3-S3

Author(s):

H. G. Hillemanns ◽

H. Madjar

Keyword(s):

Breast Cancer ◽

Early Detection ◽

Mass Screening

Download Full-text

Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review

Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics ◽

10.1055/s-0036-1597579 ◽

2016 ◽

Vol 38 (12) ◽

pp. 615-622 ◽

Cited By ~ 7

Author(s):

Tomás Reinert ◽

Susana Ramalho ◽

Rodrigo Gonçalves ◽

Carlos Barrios ◽

Marcia Graudenz ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Low Income ◽

Hormone Receptor ◽

Urban Areas ◽

Low Cost ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Breast Cancers ◽

Neoadjuvant Endocrine Therapy

AbstractBreast cancer is the most common type of cancer and the leading cause of cancer-related death among women worldwide. Hormone receptor-positive (HR+) tumors represent the most common form of this disease, with more than 70% of breast cancers expressing these receptors. Response and benefit to neoadjuvant chemotherapy (NCT) varies according to HR expression, with lower responses in luminal tumors as compared with hormone receptor-negative (HR-) and human epidermal growth factor receptor 2-positive (HER2+) tumors. Neoadjuvant endocrine therapy (NET) is an option for selected patients with HR+ locally advanced breast cancer. Neoadjuvant endocrine therapy has a favorable toxicity profile, and is associated with benefits such as having low cost and being more easily available even for cancer care professionals outside major urban areas or tertiary centers. These factors are particularly relevant, as 70% of breast cancer deaths occur in women from low-income and middle-income countries. Additionally, NET is being increasingly explored, not simply to allow for less extensive surgery, but also as a scientific tool, with the use of biomarkers to predict outcomes in adjuvant trials and for the individual patient. This review details the current and most relevant evidence about NET for breast cancer as well as the future directions of this field.

Download Full-text